Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**6-Chloropurine riboside, 5'-monophosphate** is a synthetic nucleoside monophosphate analog of adenosine monophosphate (AMP), in which the amino group at position 6 of adenine is replaced by chlorine. It acts as an experimental small molecule and has been studied primarily as a biochemical tool and research compound. Its main mechanism involves inhibition of inosine monophosphate dehydrogenase (IMPDH), an enzyme critical for purine nucleotide biosynthesis. By inhibiting IMPDH—specifically through covalent modification of the enzyme's active site cysteine residue—it disrupts guanine nucleotide synthesis and can exert antiviral and anticancer effects in vitro[4][8]. The compound has not been approved for clinical use but is used experimentally to study purine metabolism and as a potential lead structure for drug development targeting IMPDH[1][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-chloropurine riboside, 5'-monophosphate.